Novo Nordisk Looks Ahead After Tresiba Setback, Bets Against Biosimilars
The Danish pharma is focused on the latest formulation technology for insulin and GLP-1 and combinations thereof to sustain its diabetes market leader position. It’s not particularly worried about biosimilars, despite two of its top sellers coming off-patent in the next few years.
You may also be interested in...
The sharing of executive responsibilities with Kare Schultz frees up CEO Lars Sorensen to focus on key growth markets, as Novo Nordisk faces growing competitive pressures from generics, new diabetes market entrants and a tougher pricing environment.
AstraZeneca’s two-pronged approach to get its experimental fish oil-based heart drug Epanova approved by U.S. regulators is on track according to CEO Pascal Soriot. But an FDA Advisory Committee’s negative recommendation for Amarin’s similar drug, Vascepa, likely means the second step, seeking a label expansion for Epanova in a broader, less seriously ill population, will have to await full outcomes data.
Europe’s top drug advisory panel, CHMP, gave backing to Novo Nordisk’s new long-acting insulin analog as well as to new therapies from Astellas and Savient for urinary incontinence and severe gout.